{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:09:59Z","timestamp":1789042199412,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11864-021-00909-1","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:12:00Z","timestamp":1635160320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas"],"prefix":"10.1007","volume":"22","author":[{"given":"Lori A.","family":"Leslie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"issue":"20","key":"909_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"S Swerdlow","year":"2016","unstructured":"Swerdlow S, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"5","key":"909_CR2","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"issue":"27","key":"909_CR3","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362.","journal-title":"J Clin Oncol"},{"issue":"2","key":"909_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188(2):259\u201367.","journal-title":"Br J Haematol"},{"issue":"9873","key":"909_CR5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"key":"909_CR6","doi-asserted-by":"crossref","unstructured":"Rummel, M.J., et al., Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol, 2017. 35: p. ASCO Abstract 7501.","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"issue":"19","key":"909_CR7","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"issue":"14","key":"909_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"909_CR9","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","volume":"4","author":"A Davies","year":"2017","unstructured":"Davies A, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272\u201382.","journal-title":"Lancet Haematol"},{"issue":"8","key":"909_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393.","journal-title":"Lancet Oncol"},{"issue":"31","key":"909_CR11","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study. J Clin Oncol. 2019;37(31):2815\u201324.","journal-title":"J Clin Oncol"},{"issue":"9759","key":"909_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351.","journal-title":"Lancet"},{"key":"909_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejca.2020.06.017","volume":"136","author":"R Houot","year":"2020","unstructured":"Houot R, et al. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020;136:4\u20136.","journal-title":"Eur J Cancer"},{"key":"909_CR14","doi-asserted-by":"crossref","unstructured":"Brice, P., et al., Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 1997. 15(3): p. 1110\u20137.","DOI":"10.1200\/JCO.1997.15.3.1110"},{"issue":"25","key":"909_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803\u201311.","journal-title":"J Clin Oncol"},{"issue":"12","key":"909_CR16","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","volume":"15","author":"NH Fowler","year":"2014","unstructured":"Fowler NH, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311\u20138.","journal-title":"Lancet Oncol"},{"key":"909_CR17","doi-asserted-by":"crossref","unstructured":"Morschhauser, F., et al., Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med, 2018. 379(10): p. 934\u2013947. Established R2 as an alternative to CIT for select patients with treatment-na\u00efve FL.","DOI":"10.1056\/NEJMoa1805104"},{"key":"909_CR18","unstructured":"Network, N.C.C. B-cell Lymphoma (Version 1.2021). 3\/28\/2021]; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf]."},{"key":"909_CR19","doi-asserted-by":"crossref","unstructured":"Leonard, J.P., et al., AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol, 2019. 37(14): p. 1188\u20131199. First FDA-approved indication for lenalidomide in iNHL based on these data.","DOI":"10.1200\/JCO.19.00010"},{"key":"909_CR20","doi-asserted-by":"crossref","unstructured":"Andorsky, D.J., et al., MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma. J Clin Oncol, 2019. 37(15 suppl): p. abstract 7513.","DOI":"10.1200\/JCO.2019.37.15_suppl.7513"},{"key":"909_CR21","doi-asserted-by":"crossref","unstructured":"Nastoupil, L., et al., Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). Blood, 2019. 134 suppl: p. abstract 125.","DOI":"10.1182\/blood-2019-129422"},{"key":"909_CR22","doi-asserted-by":"crossref","unstructured":"Fowler, N., et al., A phase I\/II study of lenalidomide plus obinutuzumab in relapsed indolent lymphoma. Blood, 2019. 134 suppl: p. abstract 348.","DOI":"10.1182\/blood-2019-131045"},{"key":"909_CR23","doi-asserted-by":"crossref","unstructured":"Wagner-Johnston, N.D., et al., Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leuk Lymphoma, 2020: p. 1\u201311.","DOI":"10.1080\/10428194.2020.1855344"},{"issue":"11","key":"909_CR24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"909_CR25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, et al. DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912\u201322.","journal-title":"J Clin Oncol"},{"issue":"4","key":"909_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling M, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362\u201371.","journal-title":"Am J Hematol"},{"issue":"35","key":"909_CR27","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898\u2013905.","journal-title":"J Clin Oncol"},{"issue":"3","key":"909_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-021-00802-9","volume":"16","author":"J Munoz","year":"2021","unstructured":"Munoz J, Follows GA, Nastoupil LJ. Copanlisib for the treatment of malignant lymphoma: clinical experience and future perspectives. Target Oncol. 2021;16(3):295\u2013308.","journal-title":"Target Oncol"},{"key":"909_CR29","doi-asserted-by":"crossref","unstructured":"Zinzani, P.L., et al., Umbralisib, the once daily dual inhibitor of PI3K\u03b4 and casein kinase-1\u03b5 demonstrates clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the Phase 2 Global Unity-NHL Trial. Blood, 2020. 136(Suppl 1): p. Abstract 2934.","DOI":"10.1182\/blood-2020-134851"},{"issue":"20","key":"909_CR30","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411\u20135.","journal-title":"Blood"},{"key":"909_CR31","doi-asserted-by":"crossref","unstructured":"Matasar, M.J., et al., Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2021.","DOI":"10.1016\/S1470-2045(21)00145-5"},{"key":"909_CR32","doi-asserted-by":"crossref","unstructured":"Lynch, R.C., et al., Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma (CITADEL-203). Blood, 2020. 136(Suppl 1): p. Abstract 2935.","DOI":"10.1182\/blood-2020-134869"},{"key":"909_CR33","doi-asserted-by":"crossref","unstructured":"Phillips, T.J., et al., Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204). Blood, 2020. 136(Suppl 1): p. Abstract 338.","DOI":"10.1182\/blood-2020-134451"},{"key":"909_CR34","doi-asserted-by":"crossref","unstructured":"Morschhauser, F., et al., Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol, 2020. 21(11): p. 1433\u20131442. First in class approval, novel mechanism of EZH2 inhibition of interest in B-NHL, combination studies are ongoing.","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"909_CR35","doi-asserted-by":"crossref","unstructured":"Noy, A., et al., Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood, 2017. 129(16): p. 2224\u20132232. Ibrutinib active and approved in MZL, but not in FL, highlighting the importance of investigating iNHL subtypes separately in the targeted therapy era.","DOI":"10.1182\/blood-2016-10-747345"},{"issue":"11","key":"909_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"18","key":"909_CR37","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood.2020006449","volume":"136","author":"J Trotman","year":"2020","unstructured":"Trotman J, et al. Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027\u201337.","journal-title":"Blood"},{"key":"909_CR38","doi-asserted-by":"crossref","unstructured":"Opat, S., et al., Efficacy and safety of zanubrutinib in patients with relapsed\/refractory marginal zone lymphoma: initial results of the MAGNOLIA (BGB-3111\u2013214) Trial. Blood, 2020. 136(Suppl 1): p. Abstract 339.","DOI":"10.1182\/blood-2020-134611"},{"issue":"2","key":"909_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182\u201390.","journal-title":"Blood"},{"issue":"18","key":"909_CR40","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood"},{"key":"909_CR41","unstructured":"Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia. January 25 2021, AstraZeneca."},{"key":"909_CR42","doi-asserted-by":"crossref","unstructured":"Wang, M., et al., LOXO-305, A next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenstr\u00f6m's macroglobulinemia, and other non-Hodgkin lymphomas: results from the Phase 1\/2 BRUIN Study. Blood, 2020. 136(Suppl 1): p. Abstract 117.","DOI":"10.1182\/blood-2020-134314"},{"key":"909_CR43","doi-asserted-by":"crossref","unstructured":"Woyach, J., et al., Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood, 2019. 134: p. suppl 4298.","DOI":"10.1182\/blood-2019-127260"},{"key":"909_CR44","unstructured":"Jacobson, C.A., et al., Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent Non-hodgkin lymphoma (iNHL). Blood, 2020. 136(Suppl 1): p. abstract 700. First approved CAR-T product in iNHL."},{"issue":"16","key":"909_CR45","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"26","key":"909_CR46","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"key":"909_CR47","doi-asserted-by":"crossref","unstructured":"Chong, E.A., et al., CD19\u2010directed CAR-T cell therapy (CTL019) for relapsed\/refractory diffuse large B-cell and follicular lymphomas: four year outcomes Hematol Oncol, 2019. 37(suppl S2): p. 137\u2013138.","DOI":"10.1002\/hon.96_2629"},{"issue":"6","key":"909_CR48","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24(6):1172\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"909_CR49","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"909_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(2):211\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"909_CR51","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","volume":"14","author":"P Hari","year":"2008","unstructured":"Hari P, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14(2):236\u201345.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"909_CR52","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111(12):5530\u20136.","journal-title":"Blood"},{"issue":"8","key":"909_CR53","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124(8):1733\u201342.","journal-title":"Cancer"},{"issue":"8","key":"909_CR54","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"key":"909_CR55","unstructured":"Ujjani, C.S., et al., Ibrutinib and venetoclax in relapsed and refractory follicular lymphoma. Blood, 2020. 136(Suppl 1): p. Abstract 2943."},{"key":"909_CR56","doi-asserted-by":"crossref","unstructured":"Bannerji, R., et al., Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T Therapy. Blood, 2020. 136(Suppl 1): p. Abstract 400.","DOI":"10.1182\/blood-2020-136659"},{"issue":"Suppl 1","key":"909_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-134983","volume":"136","author":"E Budde","year":"2020","unstructured":"Budde E, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies. Blood. 2020;136(Suppl 1):45\u20136.","journal-title":"Blood"},{"key":"909_CR58","doi-asserted-by":"crossref","unstructured":"Hutchings, M., et al., Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood, 2020. 136(Suppl 1): p. Abstract 403.","DOI":"10.1182\/blood-2020-136044"},{"key":"909_CR59","doi-asserted-by":"crossref","unstructured":"Assouline, S., et al., Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a Phase I Dose-Escalation Trial. Blood, 2020. 136(Suppl 1): p. Abstract 702.","DOI":"10.1182\/blood-2020-135839"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00909-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00909-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00909-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:24:30Z","timestamp":1744111470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00909-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00909-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"25 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lori A. Leslie has received consulting\/advisory fees from Bayer, Seattle Genetics, ADC Therapeutics, AbbVie, Janssen, Pharmacyclics, Kite\/Gilead, AstraZeneca, and TG Therapeutics, and has received compensation for service on speakers\u2019 bureaus from Seattle Genetics, Bristol-Myers Squibb\/Celgene, Kite\/Gilead, BeiGene, Pharmacyclics\/Janssen, AstraZeneca, Epizyme, Karyopharm Therapeutics, and TG Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"111"}}